BAX 826

BAX 826 was a next-generation recombinant Factor VIII (rFVIII) treatment developed for hemophilia A. It was based on the full-length Advate (Antihemophilic Factor [Recombinant]) and utilized proprietary polysialic acid (PSA) technology to extend its circulating half-life. The PSA modification aimed to improve the pharmacokinetic profile of rFVIII, potentially allowing for less frequent dosing while maintaining bleed protection in patients with hemophilia A. It was initially developed by Baxalta and later referred to as SHP 826 under Shire following acquisition. Preclinical studies demonstrated an extended half-life compared to standard rFVIII products, but clinical development was discontinued before approval. The mechanism of action is replacement of deficient coagulation factor VIII.

Other names

PSA-Factor VIIIpolysialylated recombinant factor VIII